| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 03/28/2002 | WO2002024176A2 Treatment of tinnitus |
| 03/28/2002 | WO2001090106A3 Tryasolyl tropane derivatives as ccr5 modulators |
| 03/28/2002 | WO2001085169A3 R-eliprodil for treating glaucoma |
| 03/28/2002 | WO2001085152A3 R-eliprodil for treating glaucoma |
| 03/28/2002 | WO2001080844A3 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| 03/28/2002 | WO2001076590A3 Treatment for benign positional vertigo using antiepileptics |
| 03/28/2002 | WO2001076585A3 Use of thiamphenicol for the treatment of chlamydia pneumoniae infections |
| 03/28/2002 | WO2001058866A3 Ocular hypotensive lipids |
| 03/28/2002 | WO2001035936A3 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases |
| 03/28/2002 | WO2001032216A3 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 03/28/2002 | WO2001022955A2 Novel combination of loteprednol and antihistamines |
| 03/28/2002 | WO2001015677A3 Use of 5-ht1b/1d agonists to treat otic pain |
| 03/28/2002 | WO2000063241A9 Methods and compositions for modulating an immune response |
| 03/28/2002 | WO2000060051A3 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 03/28/2002 | US20020038035 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders |
| 03/28/2002 | US20020038030 For therapy of inflammatory conditions including migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease as well as mediation of the emetic reflex and the modulation of central nervous system (CNS) disorders such as Parkinson's |
| 03/28/2002 | US20020037929 Method of treating angiogenesis-related disorders |
| 03/28/2002 | US20020037927 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/28/2002 | US20020037900 Hydroxamic acid derivatives |
| 03/28/2002 | US20020037895 Wherein the lactone ring is modified; preventing or treating disorders or diseases mediated by LFA-1 (Leukocyte Function-associated Antigen-1) ICAM-1 (intercellular adhesion molecules) interactions; autoimmune disorders, inflammation |
| 03/28/2002 | US20020037887 Method for reducing intraocular pressure using indole derivatives |
| 03/28/2002 | US20020037886 Muscarinic agonists |
| 03/28/2002 | US20020037881 Dry eyes |
| 03/28/2002 | US20020037850 Genetic engineering; binding to antibodies |
| 03/28/2002 | US20020037848 Alzheimer's disease; Parkinson's disease |
| 03/28/2002 | US20020037584 Use of nerve growth factor for the storage, culture or treatment of cornea |
| 03/28/2002 | US20020037574 Recombinant C-proteinase and processes, methods and uses thereof |
| 03/28/2002 | US20020037549 ABC transport polynucleotides, polypeptides, and antibodies |
| 03/28/2002 | US20020037524 Nucleotide sequences for use in diagnosis, treatment and prevention of cancer, inflammation, autoimmune disease and infections |
| 03/28/2002 | US20020037297 For therapy and prophylaxis allergic rhinitis, vasomotoric rhinitis, conjunctivitis, cold, and flu |
| 03/28/2002 | CA2433157A1 Cyclopentane derivatives as therapeutic agents |
| 03/28/2002 | CA2423356A1 Zwitterionic tachykinin receptor antagonists |
| 03/28/2002 | CA2423106A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | CA2423050A1 Pyrazine derivatives as modulators of tyrosine kinases |
| 03/28/2002 | CA2422923A1 Pyridine derivatives with ikb-kinase (ikk-.beta.) inhibiting activity |
| 03/28/2002 | CA2422535A1 Treatment of diseases with adamantane derivatives |
| 03/28/2002 | CA2422527A1 Treatment of tinnitus |
| 03/28/2002 | CA2421823A1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 03/28/2002 | CA2420862A1 Protein phosphatases |
| 03/28/2002 | CA2416136A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 03/27/2002 | EP1191036A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 03/27/2002 | EP1190709A1 Treatment of tinnitus |
| 03/27/2002 | EP1190082A1 Method of inducing angiogenesis by micro-organs |
| 03/27/2002 | EP1190052A1 16405 receptor, a g-protein coupled receptor |
| 03/27/2002 | EP1190051A2 Human transport proteins |
| 03/27/2002 | EP1189946A1 ANTI-$g(a) v?$g(b)3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE |
| 03/27/2002 | EP1189941A1 Neuromedin b and somatostatin receptor agonists |
| 03/27/2002 | EP1189888A1 HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS $i(PDE 4) INHIBITORS |
| 03/27/2002 | EP1189619A1 Administration of non-oral androgenic steroids to women |
| 03/27/2002 | EP1189618A1 Thrombin inhibitors |
| 03/27/2002 | EP1189598A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 03/27/2002 | EP1189583A1 Indole derivatives |
| 03/27/2002 | EP0946562B1 PYRROLO[3,4-d]PYRIMIDINONE DERIVATIVES AND THEIR USE AS IMMUNOSUPPRESSANTS |
| 03/27/2002 | EP0946503B1 Nitromethylthiobenzene derivatives as inhibitors of aldose reductase |
| 03/27/2002 | EP0865421B1 Arylethanolamine derivatives and their use as agonists of atypical beta-adrenoceptors |
| 03/27/2002 | EP0782448B1 Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions |
| 03/27/2002 | EP0608341B1 Enzyme-orthokeratology |
| 03/27/2002 | CN1342171A Process for production of multiple cross-linked hyaluronic acid derivatives |
| 03/27/2002 | CN1342170A Process for cross-linking hyaluronic acid to polymers |
| 03/27/2002 | CN1342167A Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction |
| 03/27/2002 | CN1342163A Ketolide antibiotics |
| 03/27/2002 | CN1342083A Uses of 1-amino-3-(N,N-dimethylamino)propylidene-1,1-bisphosphonic acid |
| 03/27/2002 | CN1342077A Inhibition of formation of vascular hyperpermeability |
| 03/27/2002 | CN1342075A Liposome preparations |
| 03/27/2002 | CN1342073A Antioxidant compositions and methods for companion animals |
| 03/27/2002 | CN1341436A Eexternal-use Chinese medicine plaster for curing deafness and tinnitus |
| 03/27/2002 | CN1081635C Substituted pyrrolidine-3-Yl-alkyl-piperidines |
| 03/27/2002 | CN1081460C Use of medicine for reducing tissue damage associated with non-cardiac ischemia by aldose reductase inhibitor |
| 03/26/2002 | US6362371 β2- adrenergic receptor agonists |
| 03/26/2002 | US6362322 Conversion of a watson-crick DNA to a hoogsteen-paired duplex |
| 03/26/2002 | US6362227 Methods for the treatment of tinnitus and other disorders using R(−)ketoptofen |
| 03/26/2002 | US6362195 Inhibitor of nitric oxide synthase; central nervous system disorders |
| 03/26/2002 | US6362182 Hypotensive agents; anticholesterol agents; benign prostatic hypertropic |
| 03/26/2002 | US6361771 Implantable cell culture device comprising semipermeable membrane permitting diffusion of growth factor therethrough, and arpe-19 cells genetically engineered to produce growth factor disposed within semipermeable membrane |
| 03/26/2002 | CA2266599C Method and composition for rewetting contact lenses and relieving eye dryness |
| 03/26/2002 | CA2027665C Agent for preventing and treating opacity of lens |
| 03/21/2002 | WO2002022630A1 Purine derivatives |
| 03/21/2002 | WO2002022615A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022611A2 Caspase inhibitors and uses thereof |
| 03/21/2002 | WO2002022562A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022170A1 Insulin secretion controlling agents |
| 03/21/2002 | WO2002022168A2 Vaccine against streptococcus pneumoniae |
| 03/21/2002 | WO2002022167A2 Vaccine against streptococcus penumoniae |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022131A1 Eye drops |
| 03/21/2002 | WO2002022123A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/21/2002 | WO2002022111A2 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 03/21/2002 | WO2002008186A3 Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| 03/21/2002 | WO2001087846A3 Tricyclic pyrazole derivatives as protein kinase inhibitors |
| 03/21/2002 | WO2001087039A3 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2 |
| 03/21/2002 | WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/21/2002 | WO2001078703A3 Methods and compositions for modulating alpha adrenergic receptor activity |
| 03/21/2002 | WO2001078702A3 Methods and compositions for modulating alpha adrenergic receptor activity |
| 03/21/2002 | WO2001074379A3 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 03/21/2002 | WO2001070694A8 Amorphous torasemide modification |
| 03/21/2002 | WO2001068859A3 Il-17 receptor like molecules and uses thereof |
| 03/21/2002 | WO2001066099A3 Use of quinazoline derivatives as angiogenesis inhibitors |